Comparative Pharmacology
Head-to-head clinical analysis: ALDARA versus ZYCLARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDARA versus ZYCLARA.
ALDARA vs ZYCLARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates immune cells, leading to the production of cytokines such as interferon-alpha, which promotes antiviral and antitumor activity.
Imiquimod acts as an immune response modifier. It activates toll-like receptor 7 (TLR7), leading to the production of cytokines such as interferon-alpha, interleukin-12, and tumor necrosis factor-alpha, which stimulate both innate and adaptive immune responses.
Apply a thin layer to the target lesion(s) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 16 weeks. Do not occlude. Wash hands before and after application.
Apply a thin layer to the affected area once daily at bedtime for 2 weeks (for actinic keratosis) or up to 16 weeks (for superficial basal cell carcinoma). Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal half-life: 2-4 hours after topical application; no systemic accumulation with once-daily dosing
Terminal elimination half-life: 27 hours (range 22-33 hours) following topical application; clinical context: allows once-daily dosing
Renal: negligible; biliary/fecal: 94% as unchanged drug and metabolites
Renal: 80% as unchanged drug; Fecal: <15% as metabolites; Biliary: minimal (<1%)
Category C
Category C
Immune Response Modifier
Immune Response Modifier